Skip to content
Screener

Arrowhead Research ARWR Deferred Tax Assets and Other Non-Current Assets

Deferred Tax Assets and Other Non-Current Assets at other companies

Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$63M+4.8%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
ALN
Alnylam PharmaceuticalsALNY
Assembly Biosciences logo
Assembly BiosciencesASMB
Arbutus Biopharma Corporation logo
Arbutus Biopharma CorporationABUS
Beam Therapeutics logo
Beam TherapeuticsBEAM

Other financials

Income statement

See full
Revenue$73.7M-86.4%
Operating income-$141.3M-137%
Net income-$132.7M-136%
EPS (diluted)-$0.93-134%

Balance sheet

See full
Cash & equivalents$188.5M+1.5%
Total debt$107.9M-5.6%
Total equity$614.0M-10.1%
Total assets$2.3B+44.2%

Cash flow

See full
Operating cash flow$84.4M-81.6%
CapEx$2.6M-51.6%
Free cash flow$81.9M-82.0%

Valuation

See full
Market cap$12.38B+424%
Enterprise value$12.3B+425%
P/S19.9×+15.8×

Profitability

See full
Operating margin-35.7%+63.6pp
Net margin-48.4%+240pp
FCF margin1.8%+0.9pp

Returns & leverage

See full
Return on equity-46.4%+341pp
Debt / equity0.2×0.0×
Current ratio6.2×+1.1×

Where this comes from

Reported directly by Arrowhead Research in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The source filing: Arrowhead Research’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:05 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q1 2026
Accession
0000879407-26-000047
Line itemMarch 31, 2026September 30, 2025
Property, plant and equipment, net374,822382,515
Intangible assets, net6,0116,861
Right-of-use assets42,79443,891
Other assets4,8871,389
Total Assets$2,268,265$1,385,295
LIABILITIES, NONCONTROLLING INTEREST AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable30,747$17,674

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Arrowhead Research's deferred tax assets and other non-current assets?
Arrowhead Research (ARWR) reported deferred tax assets and other non-current assets of $4.89M in Q1 2026.
How has Arrowhead Research's deferred tax assets and other non-current assets changed year-over-year?
Arrowhead Research's deferred tax assets and other non-current assets increased by 272.5% year-over-year, from $1.31M to $4.89M.
What is the long-term trend for Arrowhead Research's deferred tax assets and other non-current assets?
Over 4 years (2021 to 2025), Arrowhead Research's deferred tax assets and other non-current assets has grown at a 50.3% compound annual growth rate (CAGR), from $272K to $1.39M.

Ask your AI about Arrowhead Research's deferred tax assets and other non-current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude